Search | Clinical Trials Finder

Conditions: Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer
Interventions: androgen ablation (AA), DC1 vaccine; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone); Biological · Drug
Lead sponsor: Cell Genesys; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 83
States / cities: Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more

Conditions: Lung Neoplasm, Carcinoma, Bronchogenic
Interventions: Lucanix; Biological
Lead sponsor: NovaRx Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 3
States / cities: Newport Beach, California • Metairie, Louisiana • Dallas, Texas

Conditions: Prostate Cancer
Interventions: aldesleukin, gene-modified tumor cell vaccine therapy, recombinant interferon gamma; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Cell Carcinoma
Interventions: Electrofusion DC vaccine; Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: GM-CSF gene transduced allogeneic vaccine GVAX; Biological
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cyclophosphamide, DRibble vaccine, Imiquimod, GM-CSF, HPV vaccine; Drug · Biological
Lead sponsor: UbiVac; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New Orleans, Louisiana • Portland, Oregon

Conditions: Prostate Cancer
Interventions: Immunotherapy allogeneic GM-CSF secreting cellular vaccine; Biological
Lead sponsor: Cell Genesys; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 12
States / cities: Laguna Woods, California • San Francisco, California • Tarzana, California + 8 more

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: Cetuximab, Pancreatic tumor vaccine, Cyclophosphamide; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
Interventions: Drug: Hyperacute Lung Cancer Cell Vaccine; Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
Interventions: Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Carcinoma, Renal Cell
Interventions: Allogeneic DCs and Autologous RCC Tumor Derived Cells; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Stage IV Melanoma
Interventions: aldesleukin, allogeneic large multivalent immunogen vaccine; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions: FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab; Drug · Combination Product
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more

Conditions: Multiple Myeloma
Interventions: Therapeutic Cellular Vaccine, GM-CSF Producing; Biological
Lead sponsor: Cell Genesys; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myelogenous Leukemia
Interventions: Vaccine; Biological
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Breast Cancer
Interventions: BCG vaccine, CD80 breast cancer vaccine, sargramostim; Biological
Lead sponsor: Providence Cancer Center, Earle A. Chiles Research Institute; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Cancer
Interventions: Ipilimumab, Pancreatic Cancer Vaccine; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer
Interventions: therapeutic allogeneic lymphocytes; Biological
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Lung Cancer
Interventions: Allogeneic B7.1/HLA-A1, Placebo; Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Hollywood, Florida • Miami, Florida

Search by objective public record fields.

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer

Biological Therapy in Treating Patients With Prostate Cancer

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy